Common Warts Drug Pipeline Report 2022 Featuring Verrica Pharmaceuticals, X4 Pharmaceuticals, Phio Pharmaceuticals, Kino Pharma, & NIELSEN BioSciences – ResearchAndMarkets.com

Common Warts Drug Pipeline Report 2022 Featuring Verrica Pharmaceuticals, X4 Pharmaceuticals, Phio Pharmaceuticals, Kino Pharma, & NIELSEN BioSciences – ResearchAndMarkets.com




Common Warts Drug Pipeline Report 2022 Featuring Verrica Pharmaceuticals, X4 Pharmaceuticals, Phio Pharmaceuticals, Kino Pharma, & NIELSEN BioSciences – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Common Warts – Pipeline Insight, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering.

This ”Common Warts – Pipeline Insight, 2022,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Common Warts pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products.

It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

The companies and academics are working to assess challenges and seek opportunities that could influence R&D Common Warts. The therapies under development are focused on novel approaches to treat/improve Common Warts.

Common Warts Emerging Drugs

Mavorixafor: X4 Pharmaceuticals

Mavorixafor as an oral, once-daily treatment for patients with WHIM syndrome. WHIM syndrome is a rare genetic primary immunodeficiency that results from “gain-of-function” mutations in the single gene that encodes for the CXCR4 receptor.

VP-102: Verrica Pharmaceuticals

VP-102, is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin (0.7% w/v) delivered via a single-use applicator that allows for precise topical dosing and targeted administration. Company is developing VP-102 for the treatment of molluscum contagiosum (molluscum), common warts and external genital warts, three of the most common viral skin diseases in medical dermatology.

Common Warts: Therapeutic Assessment

This segment of the report provides insights about the Common Warts drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Common Warts

There are approx. 5+ key companies which are developing the therapies Common Warts. The companies which have their Common Warts drug candidates in the most advanced stage, i.e phase III include X4 Pharmaceuticals

Phases

This report covers around 5+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Common Warts pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Small molecule
  • Cell Therapy
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Common Warts: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Common Warts therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Common Warts drugs.

Common Warts Report Insights

  • Common Warts Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Common Warts Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Players

  • Verrica Pharamceuticals
  • X4 Pharmaceuticals
  • Phio Pharmaceuticals
  • Kino Pharma
  • NIELSEN BioSciences

Key Products

  • Cantharidin
  • Mavorixafor
  • Diphencyprone
  • Kino Pharma Research Program
  • Albicin

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/v95mfm

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900